CWA
HARP

Capital Wealth Alliance’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Capital Wealth Alliance’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-40
Closed -$5K – 381
2019
Q4 		$5K Buy
+40
New +$6.07K ﹤0.01% 252

Other funds holding HARP

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Wealth Alliance's HARP Position: Q1 2020 in Review

Capital Wealth Alliance sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q1 2020, closing a stake of 40 shares — an estimated $5K sold.

Capital Wealth Alliance first reported a position in HARP in Q4 2019 and held it in 1 quarter. The position peaked at $5K in Q4 2019. 53 funds tracked by Wall St. Rank hold HARP as of Q1 2020.

  • Capital Wealth Alliance reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Capital Wealth Alliance sold 40 Harpoon Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $5K.
  • Capital Wealth Alliance first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Capital Wealth Alliance's Harpoon Therapeutics, Inc. Common Stock position peaked at $5K in Q4 2019.
  • 53 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Capital Wealth Alliance's 13F filing for Q1 2020, filed 28 Apr 2020.